Andrew Kenneth William Powell, Director at Aclaris Therapeutics, Inc. (ACRS), bought 500 shares at $19.12 ($10K) on 2018-05-16, disclosed to the SEC on 2018-05-17.
Open-market purchase of $10k ACRS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| MDVN | SELL | 2016-06-06 | $312K | — | Filing → |
| ITMN | SELL | 2014-09-03 | $551K | — | Filing → |
| ITMN | SELL | 2014-06-03 | $39K | — | Filing → |